Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission.

Date publication

janvier 2018

Journal

Oncotarget

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DECONINCK Eric

Tous les auteurs :
Saraceni F, Labopin M, Hamladji RM, Mufti G, Socié G, Shimoni A, Delage J, Deconinck E, Chevallier P, Blaise D, Sanz J, Huynh A, Forcade E, Savani BN, Mohty M, Nagler A,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29423053

Résumé

A preparatory regimen consisting of thiotepa-busulfan-fludarabine (TBF) has been associated with reduced relapse in patients with haematological malignancies after haploidentical and cord blood transplants; however, few data exist regarding TBF conditioning in sibling (MSD) and unrelated donor (URD) transplants for AML.

Mots clés

acute myeloid leukemia (AML), allogeneic transplantation, busulfan-fludarabine (BF), myeloablative conditioning (MAC), thiotepa-busulfan-fludarabine (TBF)

Référence

Oncotarget. 2018 Jan 9;9(3):3379-3393